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cell migration
Hongying Duan, Like Qu and Chengchao Shou*Abstract
Persistent infection of Mycoplasma hyorhinis (M. hyorhinis) was associated with gastric cancer cell migration and
invasion, but the mechanisms were not well understood. Herein, we found that M. hyorhinis activated
phosphoinositide 3-kinase (PI3K)-AKT signaling axis in gastric cancer cell lines. Epidermal growth factor receptor
(EGFR) was upstream of PI3K-AKT signaling in the context of M. hyorhinis infection, because phosphorylation of AKT
Serine 473 was almost completely attenuated by the EGFR inhibitor AG1478 or by EGFR knockdown. Phosphorylation
of AKT S473 induced by M. hyorhinis infection was also abolished by PI3K inhibitor wortmannin. Furthermore, we found
that p37, a membrane protein of M. hyorhinis, could also promote M. hyorhinis-induced PI3K-AKT signaling activation
and cell migration. In addition, pre-treatment with AG1478 or wortmannin significantly inhibited cell migration
induced by M. hyorhinis infection or p37 treatment. In conclusion, EGFR-PI3K-AKT signaling plays an important role
in M. hyorhinis-promoted cell migration in gastric cancer cells, thus providing a clue to the pathogenesis of
M. hyorhinis in gastric cancer.
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Infectious agents, such as viruses, bacteria, and parasites,
have been identified as risk factors for certain typess of
cancer [1]. The most famous are the association of Helico-
bacter pylori with gastric cancer and that of human papil-
lomavirus with cervical cancer [2,3]. Identifying the roles
of infectious agents in carcinogenesis and cancer develop-
ment will provide more efficacious methods for preven-
tion and therapies of these malignancies.
Mycoplasma hyorhinis (M. hyorhinis) belongs to myco-
plasmas (Class Mollicutes), which are small-sized, wall-
free prokaryotic organisms. The first study reporting the
association of mycoplasma with cancer was in the mid-
1960s. This study revealed the association between myco-
plasma infection and leukemia [4]. To date, there have
been several lines of clinical evidence linking mycoplasma
infection to different types of cancer [5-7]. As reported by
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unless otherwise stated.higher frequency in patients with prostate cancer than in
those with benign prostatic hyperplasia [7]. Meanwhile,
several studies including ours have reported a potential
link between M. hyorhinis infection and cancer [8-11]. We
previously examined M. hyorhinis infection in over 600
human tissues using a monoclonal antibody PD4 against
M. hyorhinis lipoprotein p37, and found that 56% of
gastric carcinoma and 55% of colon carcinoma cases were
M. hyorhinis-positive, suggesting an association between
M. hyorhinis infection and cancer [8]. Moreover, we
showed that M. hyorhinis infection in gastric cancer
tissues positively correlates with tumor metastasis [10].
The phenotypic assays revealed that M. hyorhinis could
promote cancer cell migration and invasion in vitro and
metastasis in vivo [10]. Taken together, these results
support a strong link between M. hyorhinis infection and
cancer metastasis.
p37, a lipoprotein of M. hyorhinis, has no homology
to any human proteins [12]. Our studies revealed that
p37 enhanced the invasiveness and metastasis of gastric
cancer cells in vitro and in vivo [13]. Another study re-
ported that recombinant p37 induced anaplasia andtd. This is an Open Access article distributed under the terms of the Creative
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ever, mechanisms underlying M. hyorhinis’ and p37’s
pro-invasive capacities are unclear.
Cancer metastasis is a multi-step process that includes:
1) vascularization of the primary tumor; 2) detachment
and invasion of cancer cells; 3) intravasation into lymph-
atic and blood vessels; 4) survival and arrest in the circu-
lation; 5) extravasation into distant organs; and 6)
colonization and growth of metastatic tumors [14].
Nearly 90% cancer-related mortality is caused by cancer
metastasis [15]. The signaling pathways involved in can-
cer metastasis are investigated in great detail in the past
decades [16]. Among these pathways, deregulation of
phosphoinositide 3-kinase (PI3K)-AKT signaling axis
was observed in various kinds of cancer [17]. Previous
studies uncovered the central role of PI3K-AKT signal-
ing in several cellular processes involved in cancer, in-
cluding metabolism, growth, survival, and motility
[17-20].
To clarify whether PI3K-AKT signaling is activated in
M. hyorhinis-infected gastric cancer cells and its role in
cell migration, we designed and performed this study.
We unveiled that M. hyorhinis activates PI3K-AKT
signaling in gastric cancer cells in an epidermal growth
factor receptor (EGFR)-dependent fashion. The activated
EGFR-PI3K-AKT pathway plays an important role in
M. hyorhinis-induced cancer cell migration.
Results
M. hyorhinis binds to gastric cancer cell MGC803 in a time
and dose-dependent manner
Our previous work has shown that M. hyorhinis could
infect human gastric cancer cells [8,10]. Herein, through
immunofluorescence staining with DAPI, we observed
that M. hyorhinis could attach to cell membrane. M.
hyorhinis bound to gastric cancer cell MGC803 in a time
and dose-dependent manner. When 1 × 105 CCU/mL
M. hyorhinis was added in the cell culture medium and
incubated with cells for 24 hours, peri-nuclear DNA stain-
ing was clearly seen by confocal microscopy immuno-
fluorescence assay (Figure 1A). p37 protein is the most
abundant membrane moiety of M. hyorhinis [12]. In this
study, we found that recombinant GST-p37 fusion protein,
but not GST, could adhere to MGC803 cell membrane,
as shown by immunofluorescence staining with PD4
antibody (Figure 1B), suggesting that p37 may exert
some roles in M. hyorhinis infection of human cells.
Both M. hyorhinis and GST-p37 activate PI3K-AKT signaling
We previous reported that M. hyorhinis could induce
cancer cell migration and invasion [10]. Our study also
revealed that both purified p37 protein and adenovirus-
mediated overexpression of p37 could promote AGS gastric
cancer cell invasiveness and metastasis [13]. PI3K-AKTsignaling is deregulated in a range of human cancers and is
thought to promote tumorigenesis and cancer metastasis
[21]. We noticed that phosphorylations of PI3K and AKT
were increased in M. hyorhinis-infected MGC803 and
BGC823 cells, while total levels of these two proteins were
stable (Figure 2A). When the cells were treated with GST-
p37 in different doses for 2 hours, the PI3K and AKT were
also dramatically activated (Figure 2B), suggesting that p37
alone is sufficient to induce PI3K and AKT phosphoryla-
tions uponM. hyorhinis infection.
PI3K-AKT signaling is downstream of EGFR in M.
hyorhinis-infected MGC803 cells
We found that M. hyorhinis-induced phosphorylation of
AKT S473 was attenuated by PI3K inhibitor wortmannin
(Figure 3A), confirming that PI3K is upstream of AKT
in the context of M. hyorhinis infection. PI3K-AKT sig-
naling can be activated by multiple stimuli. Growth fac-
tor receptor family proteins belong to major upstream
molecules of PI3K-AKT signaling [22]. EGFR was shown
to be involved in Helicobacter pylori-induced activation
of EGFR-PI3K signaling in AGS cells [23,24]. Interest-
ingly, phosphorylation of EGFR Y1068 was increased in
M. hyorhinis infected cells (Figure 2A). To explore the
role of EGFR in M. hyorhinis-promoted PI3K-AKT sig-
naling, we utilized EGFR kinase inhibitor AG1478 and
RNA interference strategies respectively. After AG1478
pre-treatment, we found that phosphorylation of AKT
S473 in M. hyorhinis-infected MGC803 cells was reversed
to the level similar to that in non-infected counterpart
(Figure 3A). Alternatively, when EGFR expression was
knocked down by a specific siRNA (Figure 3B), M. hyorhi-
nis infection-induced phosphorylation of AKT S473 was
also counteracted (Figure 3C).
PI3K-AKT signaling is required for M. hyorhinis infection
and induced cell migration in MGC803 cells
Next, we sought to determine the contribution of PI3K-
AKT signaling to M. hyorhinis infection. We found that
the infection of MGC803 cells were partially blocked by
AG1478 and wortmannin, as shown by lowered band in-
tensity of p37 in PCR assay (Figure 4A). Meanwhile, we
found these two inhibitors significantly lowered M. hyor-
hinis- and p37-induced cell migration (Figure 4B and C),
suggesting that activated EGFR-PI3K-AKT axis is respon-
sible for M. hyorhinis- or p37-induced cell invasiveness.
Discussion
Epidemiologic and molecular studies suggest that micro-
bial infections are associated with certain cancers. It has
been suggested that there is an association between myco-
plasma infection and different cancers [25,26]. Since the
anti-tumor monoclonal antibody PD4 was developed by
our lab [27], we sought to identify the antigen of PD4.
Figure 1 M. hyorhinis binds to gastric cancer cell MGC803 in a time and dose-dependent manner. (A) M. hyorhinis binds to MGC803 cells
in a time- and dose-dependent manner. The cells were exposed to 104, 105 CCU (color changing units)/mL of M. hyorhinis for 24 hours, or 105
CCU/mL of M. hyorhinis for 0 (unexposed), 12 and 24 hours. DAPI staining was performed at indicated time points. Titer of M. hyorhinis was
quantified as color-change-units (CCU) per milliliter. One CCU equals to one organism of mycoplasma. Unless specified, we used 105CCU/mL
M. hyorhinis to infect cells. By normalizing to the amount of cells to be infected, the multiplicity of infection (MOI) was 0.1 for 104CCU/mL and 1
for 105CCU/mL. (B) p37 binds to MGC803 cells. The cells were treated with 300 pmol GST-p37 for 24 hours. Immunofluorescence assay with PD4
antibody was performed after 24 hours. GST was used as negative control.
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Figure 2 Both M. hyorhinis and p37 activate PI3K-AKT signaling. (A) M. hyorhinis upregulates EGFR, PI3K and AKT phosphorylations in gastric
cancer cell MGC803 and BGC823. Cells were serum starved for 24 hours and then infected with M. hyorhinis for another 2 hours. Protein lysates
were analyzed by Western blot with indicated antibodies. (B) Purified p37 protein upregulates PI3K and AKT phosphorylations in gastric cancer
cell MGC803. Cells were serum starved for 24 hours and then treated with p37 for another 2 hours. Protein lysates were analyzed by Western blot
with indicated antibodies. Optical densities of protein bands were quantified by Image J software and relative expression levels of indicated
protein to loading control were shown in graph. Values represented the mean ± SD from three to four independent experiments.
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terized as a lipoprotein from M. hyorhinis, namely p37
[28]. Immunohistochemical studies utilizing PD4 sug-
gested a strong association of M. hyorhinis infection
with cancer metastasis [8,10].
Most cancer-related deaths are caused by metastasis
[15]. Several signaling pathways were shown to be re-
sponsible for this process [16]. Among them, PI3K-AKT
signaling was investigated in great detail [17-20]. In the
present study, phosphorylations of PI3K and AKT were
found to be upregulated after M. hyorhinis infection or
by treatment with recombinant p37 protein. These re-
sults suggested that PI3K-AKT signaling was activated
in the process of M. hyorhinis infection, which might bemediated by its membrane protein p37. PI3K, consisting
of a regulatory subunit p85 and a catalytic subunit p110,
is often activated by growth factor stimulation through
receptor tyrosine kinases (RTKs) [29-31]. The regula-
tory subunit, p85, directly binds to phosphotyrosine res-
idues on RTKs. This binding relieves the intermolecular
inhibition of the p110 catalytic subunit by p85 and lo-
calizes PI3K to the plasma membrane where its sub-
strate, phosphatidylinositol 4, 5-bisphosphate, resides
[30]. These RTKs are often mutated, amplified, or over-
expressed in cancers, causing aberrant PI3K activation
[30]. For example, PI3K is activated by EGFR in lung
cancers harboring somatic activating mutations in
EGFR, and by human epidermal growth factor receptor
Figure 3 PI3K-AKT signaling is downstream of EGFR in M. hyorhinis-infected MGC803 cells. (A) AG1478 or wortmannin pre-treatment
abolishes M. hyorhinis-induced AKT phosphorylation. Prior to M. hyorhinis infection, cells were pretreated with 5 μM AG1478 or 2 μM wortmannin
for 1 hour. After that, Western blot were performed. (B) Validation of silencing efficiency of EGFR. Cells were transiently transfected with 50 nM
EGFR-specific siRNAs or a control siRNA. 48 hours after transfection, cell lysates were subjected to Western blot. (C) Knock down of EGFR abolishes
M. hyorhinis-induced AKT phosphorylation. Cells were transiently transfected with 50 nM specific siRNA targeting EGFR. 48 hours after transfection,
cells were infected with M. hyorhinis for 24 hours, followed by Western blot. Optical densities of protein bands were quantified by Image J
software and relative expression levels of indicated protein to loading control were shown in graph. Values represented the mean ± SD from three
independent experiments.
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[29,32,33]. In the context of M. hyorhinis infection,
EGFR was phosphorylated and activated [10]. In this study,
to assess the role of EGFR in M. hyorhinis-induced PI3K-
AKT signaling activation, both chemical inhibition of
EGFR by AG1478 and knockdown of EGFR via RNAi were
applied. We found that M. hyorhinis infection-induced
phosphorylations of PI3K and AKT were dependent on
EGFR, therefore M. hyorhinis infection could induce
activation of EGFR-PI3K-AKT signaling. As to how M.
hyorhinis infection activates EGFR, we propose that M.
hyorhinis may bind to certain cell surface protein(s) via
p37, in turn recruiting EGFR on the cell membrane and
promoting EGFR homodimerization or heterodimeriza-
tion with other epidermal growth factor family proteins.
After dimerization, EGFR was autophosphorylated and
then phosphorylated downstream signaling targets such as
PI3K. In the future work, we will focus on the work
searching for cellular factors mediating M. hyorhinis
infection-induced downstream signaling events.
Activated PI3K catalyzes the synthesis of the membrane
phospholipid phosphatidylinositol 3,4,5-triphosphate from
phosphatidylinositol 4,5-bisphosphate, thus recruiting AKT
to the plasma membrane by direct interaction of phos-
phatidylinositol 3,4,5-triphosphate with the AKT pleckstrin
homology (PH) domain [34]. Several studies have reportedincreased AKT phosphorylation and protein expression in
tumors of the breast, prostate, ovary, and pancreas [35-38].
Once phosphorylated, AKT relocalizes to subcellular com-
partments where it phosphorylates substrates to exert dis-
tinct functions, such as cell growth, survival, anti-apoptosis
and cell migration [20,39,40]. Among the above-mentioned
cellular processes, the major function of AKT is its role in
promoting cell growth [39]. The contribution of this signal-
ing axis to cell proliferation and survival has already been
widely discussed. The classical mechanism appears to be
through activation of the mammalian target of rapamycin
complex 1 (mTORC1), which is regulated by both nutrients
and growth factor signaling [41]. However, growth and sur-
vival are not the only phenotypes that exist in carcinomas.
Additionally, cell migration and invasion are also important
phenotypes that are responsible for the progression of
primary tumors into metastases [20]. Pro-migratory func-
tion of PI3K-AKT signaling has been underscored by some
recent studies [20,42,43]. A key discovery made by the
Mercurio laboratory, showed that the alpha6beta4 integrin,
a tumor-associated antigen, promoted breast and colon
cancer cell migration and invasion by activating PI3K-AKT
signaling [44]. Furthermore, AKT can stimulate secretion of
matrix metalloproteases that are required for degradation
of the extracellular matrix [45]. In fibroblasts, AKT signal-
ing enhances activation of various small GTPases, including
Figure 4 PI3K-AKT signaling is required for M. hyorhinis infection and induced cell migration in MGC803 cells. (A) AG1478 or
wortmannin pretreatment inhibits M. hyorhinis infection. AG1478 or wortmannin was added in cell medium 1 hour prior to M. hyorhinis exposure.
Then the cells were subjected to PCR amplification of p37. (B) and (C) AG1478 or wortmannin abolishes M. hyorhinis (B) and GST-p37 (C) induced
cell migration. Transwell cell migration assay was performed according to manufacturer’s protocol. Values represented the mean ± SD from three
to four independent experiments with triplicate samples. *, P <0.05.
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eton and enhanced cell motility [46]. Similarly, expression
of activated AKT in fibrosarcoma or pancreatic cancer cells
increases their invasion through Matrigel, an effect recapit-
ulated by overexpression of AKT in breast and ovarian can-
cer cells [45,47,48]. Expression of AKT can also promote
epithelial-mesenchymal transition (EMT), a process intim-
ately associated with tumor progression to invasive and
metastatic carcinoma [49]. In the present study, we found
that AKT is activated in M. hyorhinis-infected gastric can-
cer cells, and this activation is required for M. hyorhinis-
and p37-induced cell migration in gastric cancer cells. Our
results support the point that PI3K-AKT axis plays animportant role in M. hyorhinis infection and M. hyorhinis-
induced cancer cell migration. Because AKT phosphory-
lates different targets involved in a large variety of cellular
processes, it is possible thatM. hyorhinis-induced AKTacti-
vation might affect other aspects of cellular processes, such
as anti-apoptosis, a possibility need to be validated in the
future work.
Not surprisingly, the PI3K-AKT pathway has attracted
great attention in attempts to develop specific inhibitors
as therapy for various cancers, and numerous agents were
developed [50,51]. In this study, we discovered activation
of the EGFR-PI3K-AKT pathway after M. hyorhinis infec-
tion in gastric cancer cells, which may provide valuable
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positive gastric cancer patients.
Materials and methods
Cell culture
MGC803 gastric cancer cell line was from a 53-year-old
male Chinese with poorly differentiated mucoid adeno-
carcinoma, while BGC823 gastric cancer cell line was
from a 62-year-old male Chinese with poorly differenti-
ated adenocarcinoma. Both cell lines were cultured in
RPMI-1640 medium supplemented with 10% fetal bo-
vine serum (FBS) and incubated in 5% CO2 at 37°C. The
culture media and FBS were obtained from Invitrogen
(Carlsbad, CA, US). Mycoplasma test was routinely per-
formed by PCR amplification of M. hyorhinis p37 and
DAPI staining of mycoplasma DNA.
Mycoplasma propagation and co-culture
M. hyorhinis was grown for 3–4 days at 37°C in Hayflick’s
medium [52]. M. hyorhinis was serially passaged for 3
times and harvested by centrifugation for 20 min at
12,000 g, washed once in PBS, resuspended in PBS, and
stored at −80°C. Titer of M. hyorhinis was quantified as
color change units (CCU) per milliliter as described previ-
ously [53]. MGC803 and BGC823 cells were serum-
starved for 24 hours prior to addition of M. hyorhinis.
Cells were incubated with M. hyorhinis for 24 hours be-
fore experiment.
Reagents and antibodies
GST and GST-p37 fusion proteins were expressed and
purified by our lab. AG1478 was purchased from
Sigma-Aldrich (St Louis, MO, US) and wortmannin was
purchased from Cell Signaling (Danvers, MA, US). Both
of them were dissolved in DMSO, aliquoted and stored
at −20°C. Anti-phospho-EGFR (Y1068) (#2234), anti-
phospho-PI3K (S458) (#4228), anti-phospho-AKT (S473)
(#4060), anti-PI3K (#4257), and anti-AKT (#4691) anti-
bodies were purchased from Cell Signaling. Anti-AKT
antibody (BS1784) was purchased from Bioworld (St.
Louis Park, MN, US). Anti-p37 monoclonal antibody PD4
was generated in our lab [27].
Immunofluorescence
Cells were grown on the coverslips and fixed with 4%
paraformaldehyde for 20 min at room temperature,
followed by blocking with 5% bovine serum albumin at
room temperature for 1 hour. The cells were incubated
with PD4 overnight at 4°C, followed by washing with PBS/
0.1% Tween-20 and probing with FITC-conjugated anti-
mouse antibody for 45 min at room temperature in dark.
After washing with PBS/0.1% Tween-20 for 3 times, the
cells were counterstained with DAPI and mounted on
50% glycerol/PBS. For the staining of M. hyorhinis DNA,cells were directly stained with DAPI and mounted on 50%
glycerol/PBS after blocking. A Leica SP2 confocal micro-
scope (Leica Microsystems, Dresden, Germany) was used
to observe the localization of p37 orM. hyorhinis DNA.
Small interference RNA (RNAi) transfection
Cells were plated in 12-well plates and transfected with
siRNA mate (GenePharma, Shanghai, China) according to
the manufacturer’s protocol. The target sequences were as
follows: EGFR #1 5’-CCACCUCUCUACCUUAAUATT-3’,
#2 5’-GGGCUUAGAACAACUAGAATT-3’. Negative con-
trol siRNA sequence was 5’-ACACGAGAUAAUAUCGAC
UUG-3’. siRNAs were synthesized by GenePharma
(Shanghai, China).
Western blot
Cells were washed twice with cold PBS and then lysed in
lysis buffer (25 mM Tris–HCl pH 7.4, 150 mM NaCl,
1 mM EDTA, 1% NP-40, 10% glycerol, and 1× complete
protease inhibitors). The proteins of the lysates were
quantified with BCATM Protein Assay Kit (Thermo
Fisher, Waltham, MA, US). 50 μg of total proteins were
subjected to Western blot with indicated antibodies and
GAPDH was used as loading control.
DNA extraction and detection of M. hyorhinis by PCR
DNA was isolated from cells by digestion with 50 mM
Tris pH 8.5, 1 mM EDTA, 0.5% Tween-20, and
200 mg/L proteinase K, followed by phenol/chloro-
form/isoamyl alcohol extraction and sodium acetate
precipitation. DNA precipitates were washed with 70%
ethanol, dried, and dissolved in 20 μL sterile water.
PCR was performed with 0.5 μg extracted DNA and
p37-specific primers (forward: 5’-GTAGTCAAGCAAG
AGGATGT-3’, reverse: 5’-GCTGGAGTTATTATACC
AGGA-3’) [54]. For PCR, the DNA was denatured at
94°C for 5 min first, followed by 30 cycles of 94°C for
30 sec, 50°C for 30 sec, and 72°C for 60 sec, then at 72°C
for 10 min. The PCR products were analyzed by agarose gel
electrophoresis. GAPDH was amplified as loading control.
Cell migration assay
Tissue culture-treated 6.5-mm Transwell chamber with
8.0-μm pore membranes (Corning, Corning, NY, US) was
used. Each well of 24-well plates was filled with 800 μL
medium containing 10% FBS. 3×104 cells, containing M.
hyorhinis plus inhibitors or DMSO, were transferred onto
the top chamber of each Transwell apparatus (100 μL/
chamber). Cells were incubated for 24 hours at 37°C. After
that the chambers were then fixed in methanol, stained
with hematoxylin, and counted in five randomly selected
microscopic fields per well. Each sample was prepared in
triplicate chambers and each experiment was repeated for
at least 3 times.
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The data were analyzed by ANOVA. The statistical
analysis was done using SPSS 11.0 software (SPSS) and
P <0.05 was considered significantly.
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